RecruitingPhase 4NCT05593653
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
Treating Insomnia and Improving Glycemic Control in Midlife Women With Insomnia and Pre-diabetes
Sponsor
Brigham and Women's Hospital
Enrollment
61 participants
Start Date
Jan 6, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to determine if suvorexant can help treat the severity of insomnia in midlife women who are pre-diabetic.
Eligibility
Sex: FEMALEMin Age: 40 YearsMax Age: 65 Years
Inclusion Criteria7
- Healthy women aged 40-65 years
- Postmenopausal or late perimenopausal
- Meets criteria for Insomnia Disorder
- Score on the Insomnia Severity Index (ISI) measure ≥15
- Subjective and sustained sleep disruption during screening
- Hot flashes present, including at night
- Pre-diabetic per guidelines from the American Diabetes Association
Exclusion Criteria23
- Diagnosis of other primary sleep disorders
- Shift worker
- Frequent use of hypnotic medications
- Unwillingness to refrain from taking any sleep medications during the study period
- Current major depressive episode
- Suicidal ideation
- Lifetime history of bipolar disorder, psychosis, or other serious mental health problem
- Current alcohol/substance use disorder
- Current or prior diagnosis of diabetes mellitus
- Use of an insulin sensitizer or a pharmacologic treatment for pre-diabetes
- Extreme obesity
- Current use of systemic hormonal therapies
- Renal or hepatic disease
- Pregnancy or breastfeeding
- Recent malignancy
- Recent surgery
- Neurological disorder or cardiovascular disease raising safety concerns
- Medical instability considered to interfere with study procedures
- Concomitant medications with drug interaction or co-administration concerns
- Contraindications or allergic responses to suvorexant
- Recent travel across time zones
- Excessive coffee or cigarette use
- Unwilling to limit alcohol, nicotine, and caffeine consumption during study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSuvorexant
20mg taken at bedtime for 4 weeks
DRUGPlacebo
placebo taken at bedtime for 4 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05593653
Related Trials
French Prospective Multicentric Study in Real World
NCT0703994224 locations
Optimizing Prescribing Decisions for Hospitalized Older Adults With Chronic Conditions
NCT066058071 location
Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)
NCT075184461 location
Genetics of Type 2 Diabetes in West Africans
NCT008371225 locations
Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes
NCT070616523 locations